EpiPen’s vicelike grip on the allergy shot market is about to be significantly loosened.
A competitor, the Auvi-Q from drugmaker Kaleon Inc., is set to re-enter the fray after being recalled last year, giving consumers a choice between products once again.
It’s expected to hit shelves in the first half of 2017.
Mylan’s EpiPen hit the headlines in August this year after consumers realized en masse that the potentially life-saving product had increased in price from around $50 in 2007 to $300 in 2016.
The pen, which is essentially an epinephrine autoinjector that delivers a precise dose to people with serious allergies, creeped up in price over the years. Its dominance of the market — along with an effective marketing campaign — allowed Mylan to up the cost continually, until a change in insurance policies shifted more of the financial brunt onto consumers. …
Via: Mashable: Business